Home > Insider Trading > Filing (0000899243-21-040771)

Filing Details

Accession Number:: 0000899243-21-040771
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-20 16:31:41
Reporting Period:: 2021-10-18

Accepted Time:: 2021-10-20 16:31:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1720725	Oyster Point Pharma Inc.	OYST	Biological Products, (No Disgnostic Substances) (2836)	811030955

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1746742	Clare Ozawa	C/O Oyster Point Pharma, Inc. 202 Carnegie Center, Suite 109 Princeton NJ 08540		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-10-18	303,614	$14.63	1,057,976	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	1,912	$14.63	6,518	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	242,943	$15.09	815,033	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	1,531	$15.09	4,987	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,824	Direct
Common Stock	2,236,888	Indirect	See Footnotes
Common Stock	1,003,658	Indirect	See Footnotes

Footnotes

The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by each of Versant Venture Capital IV, L.P. ("Versant IV") and Versant Side Fund IV, L.P. ("Versant Side Fund IV").
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Shares held by Versant IV. Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of Versant IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant IV, except to the extent of its pecuniary interest therein.
Shares held by Versant Side Fund IV. Versant Ventures IV is the sole general partner of Versant Side Fund IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein.
Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and the Reporting Person disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein.